Legacy App users can now access the Health Portal – just reset your password using email as username.

Revealing My Lab Results After 30 Years on Testosterone!

Revealing My Lab Results After 30 Years on Testosterone!

Member Access Required

Sign in or join the Health Portal to watch this video.

Join Now

Timeline

Timestamp
Topic
00:00
A long term testosterone history sets the stage for reviewing lab markers and risk tracking. The segment frames lab literacy as essential when hormones are used for decades.
03:32
A checklist approach is introduced that emphasizes glucose, blood pressure, cholesterol, and family history. The segment argues that priorities should be organized rather than handled randomly.
06:42
A1c is discussed with a stated value of 5.2 and clear prediabetes cutoffs. The segment emphasizes using the same units and ranges to interpret trends correctly.
10:03
Fasting glucose is shown as 64 and the transcript challenges common lab range assumptions. The segment stresses that context matters and symptoms should inform interpretation.
13:22
Kidney and liver markers are reviewed as part of routine monitoring, including creatinine, ALT, and AST. The segment treats these labs as baseline safety checks for long term androgen use.
16:40
Blood pressure targets are discussed with warnings about sustained systolic readings above 128 to 140. The segment frames hypertension control as a major lever for protecting long term health.
19:53
Lipid results are presented with a total cholesterol of 91 and LDL of 33 emphasized strongly. The segment connects very low LDL with the goal of reducing plaque progression.
23:10
Statin use is mentioned as part of the lipid strategy, with dosing described as not always daily. The segment frames medication as one tool inside a broader monitoring plan.
26:40
HDL is discussed with the warning that it can run low during androgen exposure. The segment encourages addressing overall risk rather than fixating on a single ratio.
29:46
Sleep apnea is discussed with CPAP referenced as a practical therapy that should be used consistently. The segment links breathing disruption with broader cardiometabolic stress and fatigue.
33:11
Hemoglobin and hematocrit concerns are raised, including a warning about values over 20 in some men. The segment frames thick blood risk as something that must be monitored and addressed early.
36:23
PSA screening is discussed with a stated value of 0.79 and mention of prostate exams. The segment closes by encouraging trend tracking and early interventions when markers drift.

Video Summary

The transcript presents a long term testosterone history and then opens a lab report line by line. It uses a simple checklist concept to organize health priorities around glucose, blood pressure, lipids, and family risk. A1c is highlighted early with a reported value of 5.2 and a discussion of prediabetes thresholds. Fasting glucose is shown as 64 and the speaker argues that lab reference ranges can be misleading. The message is that context, symptoms, and repeated testing matter more than one isolated number. Kidney and liver markers are also reviewed, including creatinine, ALT, and AST as routine anchors. This section frames lab literacy as a skill that becomes essential when androgens are used for decades.

Cardiovascular risk is discussed with emphasis that cholesterol numbers should be kept very low. Total cholesterol is shown as 91 and LDL is shown as 33, with repeated discussion of plaque prevention. The transcript states that blood pressure above roughly 128 to 140 systolic is harmful over time. It argues that diabetics and other higher risk groups should be even stricter with their targets. A statin is mentioned as part of the approach, although dosing is described as not necessarily daily. The discussion emphasizes that low HDL is common on androgens and should not be ignored. The core claim is that labs, diet, and monitoring can reduce risk even with long exposure history.

Sleep apnea is discussed as a major health issue that can worsen when body weight climbs. CPAP is mentioned as a therapy that should be used instead of pretending sleep is fine. The transcript links sleep apnea and androgen use to concerns about elevated hemoglobin and hematocrit. It describes men walking around with hemoglobin values over 20 and hematocrit values in a dangerous range. Prostate screening is included with a PSA value of 0.79 and mention of digital rectal exams as standard care. The message is that long term testosterone use requires a broad medical plan, not only hormone dosing. The closing encourages viewers to track trends, correct sleep, and treat labs as early warning signals.

Drug Callouts

Drug
Description
Testosterone
Testosterone is an androgen hormone used clinically for male hypogonadism and replacement therapy. The transcript reviews decades of testosterone exposure while interpreting labs like A1c, lipids, and PSA.
Statin medications
Statin medications lower LDL cholesterol and reduce atherosclerotic cardiovascular disease risk. The transcript mentions being on a statin while emphasizing very low LDL targets for plaque prevention.

Condition Callouts

Condition
Description
Obstructive sleep apnea
Obstructive sleep apnea is repeated upper airway collapse during sleep that causes hypoxia and fatigue. The transcript references sleep apnea and CPAP while discussing long term health monitoring.
Erythrocytosis
Erythrocytosis is increased red blood cell production that can raise hemoglobin and hematocrit values. The transcript warns that some men on androgens have hemoglobin over 20 with risky thick blood concerns.
Prediabetes
Prediabetes is intermediate dysglycemia where glucose regulation is impaired but diabetes criteria are not met. The transcript discusses A1c thresholds and frames 5.2 as a marker to keep in a favorable range.

Key Takeaways

  • A1c 5.2 and glucose 64 are used to explain lab context carefully.
  • Total cholesterol 91 and LDL 33 are highlighted for plaque prevention goals.
  • Blood pressure targets are emphasized because sustained hypertension destroys health over time.
  • Sleep apnea and CPAP are discussed as critical issues for long term risk reduction.
  • PSA 0.79 is presented to anchor prostate screening during testosterone use.